FLOX (Not branded (combination regimen))
Chemotherapy · Approved since 2002
Description
FLOX is a combination chemotherapy regimen consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin used in the treatment of colorectal cancer. This regimen is primarily employed in the adjuvant setting following surgical resection of colorectal tumors and in patients with metastatic disease. FLOX combines the antimetabolite activity of 5-FU with the platinum-based cytotoxicity of oxaliplatin, while leucovorin enhances 5-FU's efficacy. The regimen has demonstrated effectiveness in improving disease-free survival in stage II and III colorectal cancer patients.
Mechanism of Action
This combination targets rapidly dividing cancer cells through complementary mechanisms of DNA damage and metabolic disruption. 5-fluorouracil acts as a pyrimidine analog that interferes with DNA synthesis and RNA processing by inhibiting thymidylate synthase, while leucovorin enhances this effect by stabilizing the 5-FU-thymidylate synthase complex. Oxaliplatin forms DNA crosslinks by binding to purine bases, creating bulky platinum-DNA adducts that trigger apoptosis in cancer cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not branded (combination regimen) |
| Category | Chemotherapy |
 Status | FDA Approved |
| Administration | IV |
| Year Approved | 2002 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.